Thiopental efficacy in phenobarbital-resistant neonatal seizures

M. Bonati, G. Marraro, A. Celardo, F. Passerini, F. Schieroni, P. Spada, R. Valsecchi, E. De Capitani

Research output: Contribution to journalArticlepeer-review


The successful treatment with thiopental (10 mg/kg, i.v.) of 9 severely asphyxiated newborns, under artificial ventilation, with neonatal seizures resistant to phenobarbital, is reported in this pilot study. The clinical and electroencephalogram control of seizures was prompt and resolute. No adverse effect on cardiovascular function (heart rate, blood presssure) was observed. The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 1/h/kg, and the steady-state volume of distribution 3.6 1/h/kg. The kinetic profile of the drug compared to phenobarbital and phenytoin in newborns suggests that its action is quicker and shorter lasting. Thus, from these findings, thiopental may offer a useful and handy approach for the safe and effective treatment of phenobarbital-resistant neonatal seizures.

Original languageEnglish
Pages (from-to)16-20
Number of pages5
JournalDevelopmental Pharmacology and Therapeutics
Issue number1
Publication statusPublished - 1990


  • asphyxia
  • neonatal seizures
  • newborns
  • phenobarbital
  • thiopental pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Thiopental efficacy in phenobarbital-resistant neonatal seizures'. Together they form a unique fingerprint.

Cite this